Board of Directors
Finance & Audit Committee
Research Management Committee
Scientific Advisory Board
Commercialization & Legacy Committee
Equity, Diversity, and Inclusion Committee
Become a Member
The Board of Directors oversees the management, strategic direction and financial accountability of the Network. The Board approves GlycoNet’s policies and procedures to adhere to Network goals and mission. It is also responsible for the membership and the makeup of committees. The Board receives input from seven Board Committees: the Executive Committee, the Finance & Audit Committee, the Nominating Committee, the Research Management Committee, the Commercialization & Legacy Committee, the EDI Committee, and the Training Committee.
Samuel currently serves as a Strategic Advisor to Western Economic Diversification, and as a board member to Inspire Health, the Institute for Health Systems Transformation and Sustainability, and the Vancouver Prostate Centre, as well as a member of the Scientific Advisory Board of Quest Pharma and as a Key Opinion Leader for Quark Venture Inc.
Christine is a science executive with over 25 years of investment, advisory, business development and marketing experience. She is an expert in translating scientific data into market potential and concrete company strategy. Most recently Managing Partner and Founder of Scientia Advisors and Investments where she advised and facilitated fundraising for emerging life sciences companies, Christine has extensive experience in capital markets, strategic planning and analysis.
Dr. Acker is the Associate Vice-President (Research Integrity Support) where he has leadership responsibilities for building, implementing and managing a framework that supports programs and services encompassing all research integrity areas, including compliance, ethics certification, clinical trials monitoring, human and animal ethics, safeguarding research, and legal requirements related to research at the University of Alberta.
A highly-recognized Canadian life sciences leader, Karimah brought 30 years of dynamic global business experience to her role as CEO and Partner at Quark Venture. She previously held the position of CEO at CDRD, where she was responsible for ensuring the organization’s long-term sustainability, while leading its business functions and successfully building the many national and international alliances and strategic partnerships which are now contributing significantly to advancing the goals of CDRD.
John joined Bloom Burton & Co. in January 2012. At Bloom Burton, John’s responsibilities include M&A advisory, licensing advisory and monetization planning, as well as conducting technical and commercial due diligence on companies across all healthcare sectors. John’s area of expertise spans early-stage technologies to profitable healthcare service companies, with a particular focus on preclinical-stage biotech.
Christopher’s practice focuses on mergers and acquisitions and finance transactions, as well as advising on governance and general corporate and securities law matters. His clients include private equity and venture capital funds and companies ranging from publicly traded multinationals to early-stage ventures manufacturing.
Mariela is an immunologist and Professor at the University of Montreal. She is known for research in the areas of infectious diseases and the underlying innate and adaptive immune responses, with a particular focus on the interactions of encapsulated streptococci (such as Streptococcus suis and Group B Streptococcus) with the components of the immune system.
With more than 20 years of international experience in both the academic and private sectors, Catalina Lopez-Correa’s deep understanding of genomics and innovation has inspired leaders in science and industry to collaborate toward solving some of the world’s greatest challenges. Dr. Lopez-Correa holds a Medical degree from the UPB in Colombia, a Master’s degree in Human Genetics from Paris V University in France, a PhD in Medical Biosciences from the KULeuven in Belgium, a mini MBA from McGill University in Canada and has trained in innovation leadership at Singularity University.
Nils is a Fellow of the Chemical Institute of Canada. He currently serves as a member of three boards of not-for-profit organizations including Compute Canada, TECTERRA, and the Canadian Light Source (CLS) for which he is Chair of the Board. He recently finished terms as a member of the boards of ArboraNano, a Business-led NCE, the California Nanosystems Institute (CNSI), and the Pacific Institute for Mathematical Sciences, and as Chair of the Board of NSERC’s Strategic Network program BiopSys at the University of Toronto.
David received a PhD in chemistry at the UC Berkeley as a Chevron Fellow in the lab of Carolyn Bertozzi. His research included developing and applying the SMARTagTM platform technology to cell surface modification. Prior to joining Bertozzi’s lab, David worked at the Burnham Institute synthesizing complex glycans followed by Optimer Pharmaceuticals, where he focused on the development of glycan and macrolide based antibiotics. He was CSO, President and co-founder of Redwood Bioscience where he continued to develop novel protein conjugation methods and biotherapeutic applications such as antibody-drug conjugates.
Norma has extensive experience over a 28-year career with Merck in Sales, Marketing, Strategic Planning, Corporate Affairs, Pharmacoeconomics, Health Education and Training, Government Relations, Operations and Policy and Patient Access. Most recently she was involved in developing and management of key partnerships for Merck in Health Information Technology, and Health Data Science along with Life Sciences Accelerators/Research collaborations.
Warren is a Professor from the Department of Biological Sciences at the University of Alberta. The Wakarchuk lab investigates the structure and function of the enzymes which make and degrade various glycoconjugates. This work has been enabling the chemo-enzymatic synthesis of bioactive glycoconjugates both in the laboratory and for industrial projects. The Wakarchuk lab has expertise with both mammalian and bacterial carbohydrate active enzymes for glycan remodelling applications.
Janice Bailey has been the Scientific Director of the Fonds de recherche du Québec – Nature and Technologies (FRQNT) since 2019. The mandate of the FRQNT is to develop and promote research activities to solve challenges
and stimulate socio-economic development in a manner that will benefit Quebec and other nations. In doing so, the FRQNT prioritizes interdisciplinary international collaboration, research partnerships, and diversity in its approaches.
Louise St-Onge is the Head of Pricing, Market Access & Government Affairs at Mitsubishi Tanabe Pharma Canada. She is an accomplished Pharma Leader with >25 years executive experience and track record of achievements in Complex Specialty Pharma. Recognized as a change agent, she brings unique perspectives gained from her broad commercial & patient access experience, including in setting up Canadian Operations.
Elizabeth is the CEO of GlycoNet. She was involved in the GlycoNet initiative since the Letter of Intent stage and served as the Associate Director, Business for the Alberta Glycomics Centre from 2007–2015. Prior to her position with the Centre, she worked as a manager of large-scale and multi-institutional projects with Genome Prairie. In addition to her PhD in biochemistry, Elizabeth has an MBA in biotechnology management.
Canadian Glycomics Network
E5-33 Gunning/Lemieux Chemistry Centre
University of Alberta, T6G 2G2
© CANADIAN GLYCOMICS NETWORK (GLYCONET). ALL RIGHTS RESERVED.